NYRADA INC (ASX:NYR) 48 Performance Common Stock The Company has issued the following Performance Common Stock in the Company (Performance Shares): 2025 2024 No No At the beginning of the reporting period 18,000,000 18,000,000 Performance Common Stock expired during the year (18,000,000) - At the end of the reporting period - 18,000,000 Per note 3, on 25 November 2024, the Performance Shares reached their expiry date without satisfying the market-based vesting condition. As a result, the cumulative expense previously recognised in relation to these rights was reversed through accumulated losses during the period. No further expense will be recognised in respect of these rights. The Performance Shares would have been convertible into 18,000,000 Shares upon the achievement of the milestones referred to below on or before 25 November 2024. The fair value of each Performance Share at grant date was $0.08: Holder Performance shares Performance milestones Noxopharm Limited 6,000,300 The later to occur of: • the trading price for the Company’s CDIs achieving at least AU$0.40 for 5 consecutive trading days on the ASX; and • the Scientific Advisory Board to the Company determining that, based on in-vivo data, the final lead neuroprotectant drug candidate is ready to proceed to pre-clinical safety and toxicology studies. 6,000,300 The later to occur of: • the trading price for the Company’s CDIs achieving at least AU$0.40 for 5 consecutive trading days on the ASX; and • the Scientific Advisory Board to the Company determining that, based on in-vivo data, the final lead peripheral neuropathic pain drug candidate is ready to proceed to preclinical safety and toxicology studies. Altnia Holdings Pty Ltd 5,999,400 The later to occur of: • the trading price for the Company’s CDIs achieving at least AU$0.40 for 5 consecutive trading days on the ASX; and • the Scientific Advisory Board to the Company determining that, based on in-vivo data, the final lead PCSK9 inhibiter drug candidate is ready to proceed to pre-clinical safety and toxicology studies. Total 18,000,000 If the relevant performance milestones are not achieved on or before 25 November 2024, the Performance Shares held by each holder will be automatically redeemed by the Company for the sum of AU$1.00. Each Performance Share shall be convertible into one (1) fully paid and non-assessable Share upon the terms and conditions set forth herein. The Company will at all times reserve and keep available, solely for the purpose of issue upon conversion of the outstanding Performance Shares, such number of Shares as shall be issuable upon the conversion of all such outstanding shares; provided, that nothing contained herein shall be construed to preclude the Company from satisfying its obligations in respect of the conversion of the outstanding Performance Shares by delivery of Shares which are held in the treasury of the Company.
RkJQdWJsaXNoZXIy MjE2NDg3